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Abstract
A single-site mutant (M5) of native urokinase plasminogen activator (prouPA) induces effective thrombolysis in dogs with
venous or arterial thrombosis with a reduction in bleeding complications compared to tPA. This effect, related to inhibition
of two-chain M5 (tcM5) by plasma C1-inhibitor (C1I), thereby preventing non-specific plasmin generation, was augmented
by the addition of exogenous C1I to plasma in vitro. In the present study, tPA, M5 or placebo +/2 C1I were administered in
two rat stroke models. In Part-I, permanent MCA occlusion was used to evaluate intracranial hemorrhage (ICH) by the
thrombolytic regimens. In Part II, thromboembolic occlusion was used with thrombolysis administered 2 h later. Infarct and
edema volumes, and ICH were determined at 24 h, and neuroscore pre (2 h) and post (24 h) treatment. In Part I, fatal ICH
occurred in 57% of tPA and 75% of M5 rats. Adjunctive C1I reduced this to 25% and 17% respectively. Similarly,
semiquantitation of ICH by neuropathological examination showed significantly less ICH in rats given adjunctive C1I
compared with tPA or M5 alone. In Part-II, tPA, M5, and M5+C1I induced comparable ischemic volume reductions (.55%)
compared with the saline or C1I controls, indicating the three treatments had a similar fibrinolytic effect. ICH was seen in
40% of tPA and 50% of M5 rats, with 1 death in the latter. Only 17% of the M5+C1I rats showed ICH, and the bleeding score
in this group was significantly less than that in either the tPA or M5 group. The M5+C1I group had the best Benefit Index,
calculated by dividing percent brain salvaged by the ICH visual score in each group. In conclusion, adjunctive C1I inhibited
bleeding by M5, induced significant neuroscore improvement and had the best Benefit Index. The C1I did not compromise
fibrinolysis by M5 in contrast with tPA, consistent with previous in vitro findings.
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Introduction
Stroke is the second most common cause of death worldwide [1]
of which more than 80% are thromboembolic in origin. Tissue
plasminogen activator (tPA) is the only pharmacological reperfu-
sion treatment approved for ischemic stroke [2]. However, its
utilization has been hampered by significant problems which
include a narrow treatment window (3–4.5 hours), limited efficacy,
since only a sub-optimal dose (0.9 mg/Kg) can be administered
due to the risk of iatrogenic intracranial haemorrhage (ICH)
[3–11]. As a result, only an estimated 2-5% of ischemic stroke
patients are currently treated with tPA in the US [12], though the
number is higher in dedicated Stroke Units.
Single-chain urokinase plasminogen activator (prouPA), the
other natural plasminogen activator, was tested in stroke by a
single study [13]. ProuPA is a zymogen with little fibrin affinity but
has an equivalent fibrin specificity to tPA [14]. An intra-arterial
(ia) route of administration was used, but with a six hours
treatment window. The ia route was chosen because previous
studies showed that at therapeutic concentrations in plasma,
prouPA was vulnerable to non-specific activation to two-chain
urokinase (tcuPA). As a result, its fibrin-specificity was lost resulting
in a haemorrhagic diathesis due to degradation of clotting factors
like fibrinogen [15]. This activation of prouPA to tcuPA in plasma,
instead of only on the fibrin clot, undermined its therapeutic
exploitation and resulted in prouPA not being approved by the
European Agency for the Evaluation of Medicinal Products
EMEA. At the same time, prouPA had certain advantageous
properties, which included a much lower rate of coronary
reocclusion than tPA, no associated procoagulant haematological
effects, and a low mortality [16,17].
Therefore, structure-function and mutagenesis studies were
undertaken in an attempt to overcome this problem with native
prouPA. These led to the development of a single site-directed
(Lys300RHis) prouPA mutant, M5, which was significantly more
stable in plasma at therapeutic doses [18,19], but otherwise
retained the basic mechanism of action of prouPA. Two
thrombolytic studies with M5 in dogs with venous or arterial
thrombi showed that it was as effective as tPA but caused ten-fold
less bleeding from injury sites [20,21]. In the second of these
studies, an unusual plasma inhibitor of two-chain M5 (tcM5) was
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complications. This inhibitor, by inactivating tcM5, prevented
non-specific plasmin generation responsible for a bleeding
diathesis. The plasma inhibitor responsible was identified to be
complement C1-inhibitor (C1I) [20].
In human plasma clot lysis studies with M5, the same inhibition
of tcM5 as in the dogs was observed [20,22], and the addition of
exogenous human C1I or recombinant C1I (rhC1I) further
increased M5 stability without compromising clot lysis. As a
result, higher M5 doses achieving optimal rates of lysis were
possible without inducing fibrinogenolysis [22,23]. These in vitro
findings suggested that adjunctive C1I, which was recently
approved for treatment of hereditary angioedema, might be used
to promote both the efficacy and safety of thrombolysis with M5.
In the present study, this hypothesis was tested for the first time
in vivo, using rat stroke models of irreversible and thromboembolic
cerebral ischemia. Preliminary ex vivo studies in our laboratory
revealed that the endogenous C1I in rat plasma, in contrast to
other species, failed to complex with tcM5 and did not inhibit
tcM5 activity. This made the rat a virtual C1I knockout animal for
M5, thereby making it especially vulnerable to haemorrhagic side
effects of M5 and, by the same token, very sensitive to the effects of
human C1I. A comparison with tPA and placebo, in presence or
absence of human C1I, was then carried out.
Results
Laboratory analysis
Incubation of tcM5 showed quenching of activity within 15 min
in the plasma of each species except the rat (Figure 1). This finding
was mirrored by the absence of tcM5:C1I complexes visible on
zymography at the end of incubation. Only a faint complex with
anti-thrombin was seen, indicating that rat plasma had little
endogenous tcM5 neutralizing activity of any kind necessary to
inhibit the non-specific effects of M5. This made the rat a
functional C1I knockout species with respect to M5.
Part I (permanent ischemia): neuropathological
evaluation
Group 1 (tPA): ICH occurred starting at ,2 h from which 4 of
7 rats died within 12 hours. Extensive hemorrhagic infiltration of
the ischemic hemisphere was seen on examination. Edema and
ICH compressed the contralateral intact hemisphere as shown
(Figure 2A–C). The 3 rats that survived also showed gross ICH on
the brain surface and interhemispheric fissure. Group 2
(tPA+C1I): Only 2 of 8 rats died from ICH, and these showed
severe disruption of the ischemic cortex and underlying structures
with the lateral ventricle invaded by blood (Figure 2D). In the
remaining 6, spotty parenchymal hemorrhage was seen in 3 and
the cytoarchitecture was preserved in all of them (Figure 2E–F).
Parenchymal blood infiltration was diffuse but was confined to the
ischemic areas. Group 3 (M5): Only 4 rats were in this group for
the reasons described above. As anticipated by the findings shown
in the Figure 1, the rat is an unrepresentative species in which
excessive bleeding by M5 could be anticipated. In fact, 3 out of 4
rats died of ICH within 12 hours of the infusions and brain
sections were not obtained from any animal in this group due to
extensive necrosis and blood infiltration, which disrupted the brain
architecture (see Figure S1 B). Even in the one surviving rat,
extensive blood infiltration of the ischemic core, lateral ventricles
and subarachnoid spaces was seen, which caused severe
compression of the parenchyma with shift from the midline. The
results in this group illustrated the importance of C1I in the
prevention of hemorrhagic side effects by M5. Group 4 (M5+C1I):
With the addition of C1I, only 1 of 6 rats died of ICH at 12 hours.
This was the lowest mortality among the groups, but the difference
did not reach statistical significance. Histologically, bleeding was
mild and brain architecture was preserved in all the surviving rats
(Figure 2G–I). Group 5 (saline) and 6 (C1I): No deaths or ICH
occurred (Figure 2L–N, Table 1).
Part I Summary. ICH and mortality were high with both
activators alone, but highest with M5 consistent with the absence
of C1I effect in rat plasma. C1I pretreatment reduced ICH and
mortality dramatically, confirming its importance in preserving the
fibrin specificity of M5 (Group 2). C1I also reduced ICH with tPA,
but this was related to inhibition of fibrinolysis, as evidenced by the
results in Part II. Semiquantitative measurement of bleeding
showed that C1I significantly reduced ICH by M5 compared to
tPA (p=0.02), whereas the C1I reduction of ICH by tPA did not
reach significance (p=0.14) (see Intracranial hemorrhage section
below).
Part II (thromboembolic ischemia)
Functional outcome. All rats survived for 24 hours after
stroke except for 1 out of 6 given M5 alone. This one died of lethal
ICH 8 hours after treatment, which was associated with profuse
rebleeding from the tail, the only animal in which this was seen.
The pretreatment neuroscore at 2 h ranged from 3.0–3.6 in the 6
groups, whereas at 24 h it ranged from 2.0–3.0 (Table 1). Group 4
had the lowest score at 24 h and was the only group where the
difference between 2 h and 24 h was significant (p=0.016)
(Figure 3A).
Ischemic volumes. The ischemic areas were readily
identified after TTC staining, facilitating measurement (Figure 3B
and Figure 4). Compared to their respective controls (Groups 5 &
6), thrombolysis reduced ischemic volumes significantly and to a
similar extent with tPA (Group 1, p=0.004), M5 (Group 3,
p=0.009) and M5+rhC1I (Group 4, p=0.004), with brain salvage
being 60%, 54% and 61% respectively. This showed that the
fibrinolytic effect of tPA alone and M5 with or without rhC1I was
comparable. With the addition of rhC1I to tPA (Group 2), the
ischemic volume increased ,40% (85R142 mm
3), indicating an
inhibition of fibrinolysis by the C1I. As a result, brain salvage was
no longer significant (p=0.12) in this group. By contrast, the
combination of rhC1I with M5 (Group 4) was associated with a
further, small reduction in ischemic volume (99R88 mm
3)
(Figure 3B, Table 1).
Edema Volumes. Among the treatment groups, the edema
volume with tPA was the highest (56617) as compared to 36611
for M5+C1I. With the addition of rhC1I to tPA, the edema
volume was reduced to 35618. This inhibition of tPA-mediated
edema by rhC1I was surprising since it was accompanied by a
,40% increase in ischemic volume, which would have been
expected favor edema formation. Since the rhC1I had no effect on
edema formation in control groups 6 vs. 5, the rhC1I effect could
not be attributed to an inhibition of BBB disruption by ischemia.
Instead, the findings implicate tPA-mediated BBB disruption as
the C1I target (Figure 3B, Table 1).
Intracranial Hemorrhage (Part I and II)
ICH mortality (Part I). Out of the 14 rats in the four
treatment groups given C1I, there were 3 deaths, compared with
the 11 rats not given C1I in which there were 7 deaths. The
addition of C1I significantly (p=0.04) reduced ICH mortality by
inhibiting bleeding.
ICH semiquantitation (Part I). The inspection of
microscopic fields at 10x magnification showed differences in the
amounts of blood infiltration among Groups 1, 2 and 4 (Figure 5A,
M5 in the Acute Treatment of Stroke
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included in this analysis due to the large extent of the bleeding, as
anticipated by the absence of tcM5 inhibition in rat plasma
(Figure 1). By contrast, with the addition of C1I (Group 4), only
7.7%62.2 of the microscopical fields were found infiltrated by
blood, which was was significantly (p=0.02) less than with tPA
(Group 1) in which 38.1%69.9 were infiltrated. With the addition
of C1I (Group 2) bleeding was reduced to 21.1%68.4 but this was
insignificantly different from the others. Anatomically, surface
infiltration predominated in all groups, and was least in Group 4,
in which only 5.6%62.3 surface fields were infiltrated, compared
to 21.7%65.7 in Group 1 (p=0.015) and 10.6%63.3 in Group 2
(p=0.38). Similarly, at the cortex and striatum Group 4 showed
the least infiltration compared to Group 1 and 2, although these
differences were not statistically significant.
Part II (ICH visual score). ICH was not seen in any of the
control rats (Groups 5 and 6), indicating that it was related entirely
to the effect of thrombolysis in this model, and none of the control
rats died. The ICH visual score was most severe with tPA (2.560.6)
and M5 alone (2.360.5), in which one rat died associated with
profuse bleeding from the transected tail wound, indicating a
systemic hemorrhagic state (Table 1). With adjunctive rhC1I
(Group 4), ICH was again reduced (1.760.3). In Group 2, rhC1I
also inhibited ICH (1.860.5), but this was associated with inhibition
of fibrinolysis, as reflected by a ,40% increase in ischemic volume.
Benefit Index. The Benefit Index defined as the ratio of
brain salvage and bleeding complications (ICH) was greatest for
Group 4, though the difference between it and Group 1 did not
reach statistical significance (p=0.29). The mean values and SEM
are shown (Figure 5B).
Discussion
TPA has remained the only thrombolytic available for clinical
use in ischemic stroke since its approval in 1997 [2]. It is the
standard against which new thrombolytics must be compared. In
view of the well documented limitations of tPA, a new
thrombolytic should optimally have a greater reperfusion rate
than tPA, not have a similar dose limitation by ICH complications
[24,25]; have larger treatment window; and no blood brain barrier
(BBB) disruption [26,27] or neurotoxicity [8,11].
In Part I of the present study, irreversible ischemia was used to
evaluate differences in hemorrhagic complications of the throm-
bolytic regimens, especially the salutary effects of C1I. In order to
enhance the hemorrhagic side effects, thrombolysis was delayed
four hours after the ischemia. As a result, fatal ICH occurred in as
many as 57% and 75% of rats with tPA and M5 respectively.
Since the rat is relatively resistant to tPA, 10 mg/kg, more than
ten-times higher than the human dose, is needed for efficacy [28],
and is the dose used in most studies in the literature [26,29–32].
The rat is even more resistant to human uPA, so 15 mg/Kg M5
was used [14].
C1I administration reduced ICH mortality with M5 to 17% of
rats (Group 4), and significantly reduced blood infiltration in the
microscopic fields (Figure 5A). This finding demonstrated the
salutary effect of C1I on bleeding complications by M5 for the first
time, which heretofore, had only been show in vitro as an effect on
non-specific plasminogen activation by M5 during clot lysis
[22,23]. Importantly, the C1I inhibition of bleeding was not
accompanied by any reduction in thrombolytic efficacy by M5, as
shown in Part II by the equivalent ischemic volumes in Groups 3
and 4. This finding was also consistent with that obtained from clot
lysis studies with M5 and C1I [22].
C1I also reduced fatal ICH to 25% with tPA (Group 2) and
reduced blood infiltration in the microscopic fields, but not to a
significant degree. In contrast to M5, this C1I effect was
accompanied by a major inhibition of fibrinolysis, as evidenced
by a ,40% increase in ischemic volume by C1I compared to tPA
alone, as shown in Part II. Therefore, the C1I inhibition of
bleeding complications without impairing thrombolysis only
occurred with M5, reflecting fundamental differences in these
two plasminogen activators.
M5 is a proenzyme which requires plasma inhibitors, principally
C1I, to prevent its non-specific activation to tcM5 (see Figure 6A).
When this occurs, its fibrin-specificity is lost resulting in bleeding
complication due to plasminemia. This C1I effect in preventing this
non-specific plasminogen activator effect is analogous to that of
plasminogen activator inhibitor-1 (PAI-1) in controlling the physio-
logical function of prouPA [33]. However, the endogenous
concentration of C1I is much greater than that of PAI-1 [15], and
can be further supplemented by exogenous C1I, as shown in the
present study. In addition, C1I is a weaker inhibitor than PAI-1 [34],
Figure 1. Quenching of tcM5 activity by inhibitors in plasmas from different species. A. tcM5 (10 mg/mL) incubated (37uC, 1 h) in plasma
and activity monitored with uPA enzymatic substrate (S2244). Rat plasma induced little tcM5 inhibition, in contrast to the other plasmas. B. After 1 h
of incubation, each plasma sample was examined by zymography. No tcM5 complex with C1I, and only a faint complex with AT formed in rat plasma,
in contrast to the other species.
doi:10.1371/journal.pone.0021999.g001
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fibrin-dependent plasminogen activation [23], explaining why
thrombolysis was not inhibited by C1I. By contrast, tPA is an
enzyme in both its single and two-chain forms so that its fibrin-
specific properties are not dependent on plasma inhibitors.
Furthermore, tPA and prouPA are complementary and syner-
gistic [35] in their fibrin-dependent plasminogen activation,
which also helps explain a difference in their effect on hemostatic
fibrin. TPA binds to fibrin at a site on the D-domain of intact
fibrin where it activates plasminogen bound to this site [36,37].
This so-called ternary complex promotes plasminogen activation
by tPA as much as 1000-fold [38]. ProuPA/M5 has no fibrin
affinity but has a high substrate affinity [37], which is to
plasminogen bound to the fibrin E-domain [39], which is found
only on degraded fibrin. Hemostatic fibrin, being protected from
degradation, contains the D but not the E-domain (see Figure 6B).
Therefore, unlike tPA, M5 spares hemostatic fibrin, as previously
reported [20], but this is highly dependent on the prevention of
non-specific conversion to tcM5. Therefore, M5 is highly
dependent on plasma inhibitors (C1I), which is not the case for
tPA. Bleeding by tPA is believed to be principally related to its
lysis of hemostatic fibrin due to its fibrin binding site being on
intact fibrin like hemostatic fibrin [40] (Figure 6B).
The tPA dose in Part II was reduced to 5 mg/K due to the high
ICH rate in Part I. In addition, rhC1I (equivalent in per unit
activity to plasma C1I) was substituted for C1I purified from
human plasma. As in Part I, M5 alone (Group 3) induced severe
ICH and profuse re-bleeding from the transected tail, reflecting a
systemic hemorrhagic state, results consistent with the absence of
tcM5 inhibitory activity in rats (Figure 1). Pre-treatment with
rhC1I virtually eliminated M5 bleeding, and this group (Group 4)
was the only one with significant improvement in neurofunction
after thrombolysis (Figure 3A). The inhibition of ICH by C1I was
semiquantitated by a standardized visual score, which showed
significant (p=0.02) reduction in overall ICH in Group 4
compared with Group 1 or 3 (Figure 5A).
The post-treatment ischemic volumes were comparable in
Groups 1, 3, and 4, showing that their fibrinolytic effects were the
same, whereas the addition of rhC1I to tPA(Group 2) resulted in a
,40% increase in ischemic volume reflecting inhibition of tPA
mediated fibrinolysis by rhC1I, in contrast to its effect on M5. The
edema volume associated with tPA was consistent with its known
Figure 2. (Part I): representative brain sections from Groups 1, 2,4. A–C: Rat which died from tPA showing extensive hemorrhagic infiltration
with edema compression (arrows) of the ischemic hemisphere (enlarged in C). D: Diffuse hemorrhagic transformation of ischemic cortex with edema
compression in a Group 2 rat which died of ICH in a few hours. E–F: Sections 24 h after tPA+C1I infusion showing blood within the ischemic core
(arrowheads), but no infiltration below the cortical surface (details in F). G–I: Thick surface hematoma above ischemic area, but no major blood
infiltration in a M5+C1I rat. This Group showed the least bleeding with no alteration of brain architecture. L–M: ischemic sections from saline group,
showing no blood infiltration within the infarct areas (details in N). Scale bars: 2 mm in A–B–D–E–G–H–L–M and 500 mm in C–F–I–N. Group 3 (M5
alone) rats not shown due to extensive disruption of brain by ICH.
doi:10.1371/journal.pone.0021999.g002
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mean±SEM Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
tPA tPA+C1I M5 M5+C1I saline control saline+C1I
Part I N7 8 4 6 5 5
treatment protocol alteplase 10 mg/kg C1I 100 IU/kg M5 15 mg/kg C1I 100 IU/kg saline C1I 100 IU/kg
alteplase 10 mg/kg M5 15 mg/kg
% animals died due to bleeding (n) 57.1 (4) 25 (2) 75 (3) 16.6 (1) 0 (0) 0 (0)
% animals with parenchymal
hemorrhage (n)
71.4 (5) 50 (4) 75 (3) 33.3 (2) 0 (0) 0 (0)
% animals with surface hematomas (n) 71 (5) 75 (6) 75 (3) 66.6 (4) 0 (0) 0 (0)
total hemorrhage (% 10x m.f.) 38.169.9 21.168.4 - 7.762.2 2.560.8
subarachnoidal hemorrhage
(% 10x m.f.)
21.765.7 10.663.3 - 5.662.3 1.360.3 -
intracortical hemorrhage
(% 10x m.f.)
10.663.7 6.463.2 - 1.760.2 1.160.6 -
subcortical hemorrhage
(% 10x m.f.)
5.862.5 4.162.9 - 0.360.2 0.160.06 -
Part II N6 4 6 6 5 4
treatment protocol alteplase 5 mg/kg rhC1I 180 IU/kg M5 15 mg/kg rhC1I 180 IU/kg saline saline
alteplase 5 mg/kg M5 15 mg/kg rhC1I 180 IU/kg
mean ischemic volume (mm
3)8 5 619 142615 99641 88630 213628 228613
mean % ischemia 8.561.7 14.461.1 9.463.6 8.763.0 19.962.2 21.760.9
mean % ischemic brain salvage
following thrombolysis
60.168.9 37.566.8 53.5619.3 61.3613.1 0613.2 065.9
mean edema volume (mm
3)5 6 617 35618 51616 36611 69618 74622
mean % edema 5.662.0 3.461.7 4.961.4 3.661.1 6.561.6 6.761.6
neuroscore at 2 h 3.060.3 3.560.3 3.260.2 3.360.2 3.260.4 3.560.3
neuroscore at 24 h 2.560.3 2.560.3 2.560.6 2.060.4 2.860.4 3.060.0
ICH visual score 2.560.6 1.860.5 2.360.5 1.760.3 1.260.2 1.360.3
Benefit Index 0.2460.05 0.2160.06 0.2360.08 0.3760.10 - -
doi:10.1371/journal.pone.0021999.t001
Figure 3. (Part II) Neuroscores (A) and Ischemic and Edema volumes (B). A: Neuroscore pre-(2 h) (black) and post-treatment (24 h) (gray) of
thromboembolic stroke. Only Group 4 (M5+C1I) showed significant (*p,0.05) post-treatment functional recovery. B: Ischemia volumes (black) in all
groups. Differences were significant (*p,0.05, **p,0.01) from control in all but Group 2 (tPA+C1I). Edema volumes (gray) in all groups. In Group 2
(tPA+C1I), C1I increased the ischemic volume but decreased the edema volume, showing an unusual discordant relationship.
doi:10.1371/journal.pone.0021999.g003
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Interestingly, the addition of rhC1I reduced the edema volume by
almost 40% (Figure 3B, Table). Since no direct effect of rhC1I on
ischemia-mediated BBB disruption was seen in placebo Group 6 vs
5, the rhC1I effect was related to tPA-induced edema formation,
suggesting that complement activation may have been involved. It
has been reported that tPA activates the complement pathway in
vivo, generating anaphylatoxins in patients treated with tPA for
coronary thrombosis [42].
Since the net clinical benefit of thrombolysis corresponds to the
positive effects of reperfusion and the negative effects of ICH, an
attempt was made to calculate a ‘‘Benefit Index’’ by combining the
two (Figure 5B). In an analogous way the Clinical Utility Index has
been recommended for drug development [43]. The Benefit Index
was greatest for Group 4, though this did not reach statistical
significance (Figure 5B), and correlated with the neuroscore
improvement in Group 4 (Figure 3A).
In conclusion, a prouPA mutant, M5, was tested in two rat
stroke models against the effects of tPA, the current standard.
The ICH and ICH mortality were greatest with M5 and tPA, but
were significantly (p=0.04) reduced by the addition of C1I. No
ICH was seen in either of the placebo groups showing that in this
model, ICH was a side effect of thrombolysis. In Part II, the
ischemic volume reductions by tPA, M5, and M5+rhC1I were
equivalent, allowing their complication rates to be compared.
ICH was again greatest with M5 and tPA, and the addition of
rhC1I to M5 prevented this without impairing thrombolysis by
M5. By contrast, when rhC1I was combined with tPA, both ICH
and thrombolysis were inhibited, reflecting an important
difference in the mechanisms of action of these two plasminogen
activators.
The findings provide the first demonstration that exogenous
C1I prevents bleeding complications by M5 without interfering
with thrombolysis, an effect which heretofore had been shown only
in vitro as an inhibition of non-specific plasminogen activation by
M5 during clot lysis [22,23]. Since thrombolytic efficacy is
currently limited by dose dependent ICH (requiring tPA dose to
be restricted to 0.9 mg/Kg), a thrombolytic with a selective
antidote for ICH would not have this limitation and could improve
thrombolytic efficacy in stroke to an unprecedented degree.
Materials and Methods
Ethical statement
Male adult Sprague-Dawley rats (Harlan, Italy) weighing 270–
350 g were used in this study. All animal experimental procedures
were approved and carried out in accordance to European
Community Council Directive 86/609/EEC (November 24,
1986), Italian Ministry of Health and University of Turin
institutional guidelines on animal welfare (law 116/92 on Care
and Protection of living animals undergoing experimental or other
scientific procedures; authorization number 17/2010-B, June 30,
2010) and ad hoc Ethical Committee of the University of Turin.
Figure 4. (Part II): Brain infarct zones from representative rats
in each group. Five antero-posterior TTC stained 2 mm-thick coronal
sections from a representative animal from each group. Infarct areas in
cerebral cortex, hippocampus and striatum appear white. The least
amounts of infarction were with tPA, M5, and M5+rhC1I. Scale bar:
5 mm.
doi:10.1371/journal.pone.0021999.g004
Figure 5. Semiquantitative ICH from Part I (A) and Benefit
Index from Part II (B). A. ICH (%) by anatomical region in Groups 1, 2
(tPA) and 4 (M5+C1I). Group 3 could not be examined microscopically
due to extensive hemorrhage. Extent of ICH in Group 4 was
significantly (*p,0.05) less than in Group 1. B. Benefit Index defined
as brain salvage divided by ICH complications. Brain salvage=control -
post treatment ischemic volume/control ischemic volume. ICH
complications=ICH score. The mean of the ratios and SEM for each
treatment group is shown. Group 4 had the best Benefit Index but the
difference from the other groups did not reach statistical significance
(p=0.29).
doi:10.1371/journal.pone.0021999.g005
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were made to minimize suffering and limit the number of animals
used.
Experimental plan
To help evaluate the species suitability of the rat for this study of
M5, rat plasma was compared with other species before
performing any surgical procedure. TcM5 (10 mg/mL) was
incubated (37uC) 1h in plasma from rat, human, dog, guinea pig
and rabbit. The quenching of tcM5 activity was monitored over
1 h with uPA amidolytic substrate (S2244). After 1 h incubation,
the plasmas were examined by zymography on plasminogen
enriched casein plates as previously described [20], a method
sensitive to plasminogen activator:inhibitor complexes. Male adult
Sprague-Dawley rats (Harlan, Italy) weighing 250–350 g were
used to compare therapeutic fibrinolysis by tPA or M5+/2 C1I
following middle cerebral artery (MCA) occlusion. In Part I
(n=35), we evaluated intracranial hemorrhage (ICH) complica-
tions with a model of irreversible ischemia by permanently
occluding the MCA. Survival and anatomical findings at 24 hours
in surviving animals were monitored. In Part II (n=31),
thromboembolic MCA occlusion was used and ischemic volume,
edema volume, ICH, and functional recovery were evaluated at
24 hours. Rectal temperature was maintained at 36.5–37.5uC
Figure 6. Illustration of ProuPA vs M5 at therapeutic concentrations in plasma and of the lysis of hemostatic vs occlusive fibrin by
tPA and M5. A. At therapeutic concentrations of prouPA or M5, their intrinsic activities can activate plasminogen in plasma and the plasmin
generated will then activate these proenzymes to their respective enzymes uPA and tcM5. The latter is irreversibly inactivated by C1I, which prevents
the positive feedback, thereby preventing non-specific plasmin generation responsible for hemorrhagic side effects. B. Hemostatic fibrin, being
protected from degradation physiologically, contains only the plasminogen binding site on the fibrin fragment-D domain of intact fibrin. At
therapeutic concentrations, tPA, being free of its inhibitor PAI-1, will bind to an adjacent site to plasminogen resulting in its activation and bleeding
from the degraded hemostatic site. Occlusive thrombus triggers the release of tPA from the vessel wall which initiates its degradation physiologically.
This exposes new plasminogen binding site, particularly the high affinity site on fibrin fragment E domain with its three C-terminal lysine.
Plasminogen binding to this site undergoes a conformational shape change which permits its activation by M5 causing lysis. TPA will also lyse the
occlusive clot since other plasminogen binding sites remain. The two plasminogen activators are complementary and synergistic in their fibrinolytic
mechanisms.
doi:10.1371/journal.pone.0021999.g006
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Varese, Italy).
Materials
M5 was expressed in Escherichia coli as previously described [20]
and obtained from Primm (Milan, Italy). C1I purified from human
plasma (Berinert PH) was kindly supplied by Behring GmbH
(Marburg, Germany); rhC1I was kindly supplied by Pharming
(Leiden, The Netherlands), and tPA (ActilyseH, Boehringer
Ingelheim, Germany) was a generous gift of dr. Bergui
(Department of Neuroscience, University of Turin).
Treatment protocols. Infusions of tPA or M5 were
administered by pump (KD Scientific, Holliston, MA, USA)
through the right femoral vein under 2% isoflurane anesthesia
with 10% of the total dose given as a bolus at outset and the
remainder over 30 minutes. The tPA dose for part I was 10 mg/
Kg, the dose used in most published studies in rat stroke [26,29–
32] and was given 4 h after the MCA occlusion. Because of the
high incidence of fatal bleeding complications in Part I, the tPA
dose was reduced to 5 mg/Kg for Part II and all treatments were
administered 2 h after occlusion. The M5 dose of 15 mg/Kg was
used in both Part I and II, and was estimated from results of
comparative clot lysis data in rat plasma; in a preliminary
experiment, this dose was found effective to dissolve clot and re-
establish adequate blood flow as confirmed by laser doppler
flowmetry profile (LDF, see Figure S1 A online).
The C1I (100 IU/kg) in part I or rhC1I (180 IU/kg) in part II
was administered as a bolus before fibrinolysis. The per IU
activities of C1I and rhC1I were shown to be equal (unpublished
observations).
Experimental groups
In both Part I and II, before MCA occlusion, the animals were
randomly assigned to the following 6 groups through computer-
generated randomization schedules: (1) tPA; (2) tPA+C1I; (3) M5;
(4) M5+C1I; (5) saline control; (6) saline+C1I. Group 3 was
allotted the fewest rats since the absence of endogenous C1I
activity in the rat (Figure 1) made hemorrhagic complications so
likely that little variability was anticipated.
Part I. Permanent ischemia to evaluate hemorrhagic
complications (35 rats). The MCA was cauterized by the
method described by Renolleau [44]. Rats were anesthetized with
isoflurane (4% during induction, then maintained with 1.5%), in a
mixture of 30:70 O2/N2O delivered with a face mask throughout
the surgery duration. Briefly, under an operating microscope (Carl
Zeiss Inc., Jena, Germany), a midline incision of the head was
performed, the temporal muscle dissected and the temporal bone
exposed; a burr hole was drilled very close to the zygomatic arch
and the left MCA was identified. The MCA main branch was then
electrocoagulated close to its origin at the junction with the
olfactory branch. Thereafter, a median incision was made in the
neck to expose the left common carotid artery (CCA), which was
transiently occluded by a clip in order to reduce infarction size
variability due to anastomoses in the MCA territory. After 90
minutes, the clip was removed. Cortical blood flow variations from
ischemia were not measured in this part, as MCA was cauterized
under visual control and successful occlusion was confirmed by
progressive whitening of the cortex. Infusions were initiated 4h
later.
Neuropathological examination
After 24 h, the surviving rats were given a lethal dose of chloral
hydrate and then perfused through the left ventricle with saline
followed by fixative (paraformaldehyde 4% in 0.1 M phosphate
buffer, PB, pH 7.4). Brains were then removed, post-fixed for 3 h
in the same paraformaldehyde solution, infiltrated overnight in
30% sucrose in PB for cryoprotection and stored at 220uC. Brains
were sectioned on the cryostat in 50 mm-thick serial sections; every
sixth slice was mounted on gel-coated slides and stained with cresyl
violet for histological evaluation and semiquantitation of hemor-
rhagic infiltration.
Semiquantitative analysis of bleeding
In order to measure the extent of hemorrhagic infiltration of the
brain, in the Groups 1, 2 and 4 (this was not possible for Group 3
due to massive hemorrhagic destruction of tissue) every sixth
section was inspected under the microscope (at 10x magnification)
and compared to saline group (Group 5; Group 6 was not included
in analysis as no evidence of macroscopical hemorrhage was
found, similarly to Group 5). For each section, the total number of
microscopic fields (m.f.) was inspected (mean 754 fields 615 per
animal) and the number infiltrated by blood was counted, with
reference to location (cortical surface, cerebral cortex or striatum).
The data were expressed as percentage of fields infiltrated by
blood in each area.
Part II: Thromboembolic ischemia (31 rats). All infusions
(tPA 5 mg/kg or M5 15 mg/kg or placebo) were administered 2 h
post occlusion. RhC1I (180 IU/kg) was administered as a bolus
before the infusions. Ischemia was induced by injection of
autologous blood clots in suspension into the internal carotid
artery (ICA), as described by Busch [45]. In order to prepare blood
clots for embolism, femoral arterial blood from a donor rat was
collected into a 20 cm long PE-50 catheter and retained for
2 hours at room temperature and subsequently at 4uC for
22 hours to allow clot formation to go to completion. Clots were
pushed out of the catheter with a saline-filled syringe, rinsed
several times in a Petri dish containing phosphate-buffered
solution (PBS, pH 7.4), in order to remove blood cells and
obtain a white clot, then inspected under the microscope to select
fibrin-rich fragments. These fragments were cut into 2 mm-long
pieces and transferred into a solution containing 1 mg/mL
albumin in PBS to allow clot retraction. Approximately 2 hours
later, 20 fibrin-rich fragments were drawn up in the albumin
solution in one meter-long PE50 catheter, taking care to maintain
,3 cm distance between clots in order to keep them apart, and all
embolized into MCA origin.
Surgical procedures
Rats were anesthetized with isoflurane (4% during induction,
then maintained with 1.75%), in a mixture of 30:70 O2/N2O
delivered with a face mask throughout the surgery duration. After
a longitudinal incision of 2 cm in length in the midline of the
ventral cervical skin, left CCA, internal (ICA) and external carotid
artery (ECA) were carefully dissected and exposed, avoiding any
damage to the adjacent vagus nerve. Inferior thyroid and occipital
arteries, branching from ECA, were visualized and cauterized; the
distal portion of ECA was ligated and cut along with the terminal
lingual and maxillary artery branches, and the carotid bifurcation
identified. ICA was dissected cranially up to the origin of
pterygopalatin branch, which was ligated using a 6/0 suture. A
5-0 silk suture was loosely tied around the origin of ECA, and then
the CCA and ICA were temporarily clamped using microvascular
clips. A PE-50 catheter containing blood clot suspension with a
modified 0.3 mm outer diameter was introduced into the ECA
stump through a small puncture and advanced 1–2 mm beyond
carotid bifurcation; the 5/0 suture was tightened around the
catheter to prevent backflow bleeding. The clip around ICA was
removed and clots injected within 30 s, while CCA was still
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ECA stump was ligated and the CCA clip removed, so that blood
pressure could push clots cranially. The wound was then closed; the
rat wasallowed tocompletely recover fromanaesthesiaandreturned
to its cage. The surgery was complete in approximately 30 minutes.
Laser Doppler flowmetry (LDF)
Occlusion was confirmed by LDF using Biopac LDF100C
(Biopac Systems, CA, USA), using an optical fibre probe
positioned 0.5 mm above the dural surface, 1 mm posterior and
5.5 mm lateral to the bregma. Recordings of cortical blood flow
(CBF) in the MCA territory were started 30 minutes before
occlusion and CBF changes were expressed as percentage of pre-
ischemic value; a 70% drop from the baseline levels indicated
successful occlusion. Time profile of recanalization was not further
investigated as LDF was previously shown not to reliably predict
thrombolysis-mediated reperfusion [46].
Re-bleeding
The rat tail was transected 5 mm from the tip and allowed to
stop bleeding before thrombolysis was initiated. Re-bleeding from
this site, reflecting lysis of hemostatic fibrin, was monitored.
Functional neuroscore
Functional outcome was tested at 2 and 24 h by observers
blinded to the pharmacological regimen. A 5 point scale described
by Longa [47] was used (grade 0: no neurological deficit; grade 1:
failure to fully extend left forepaw; grade 2: contralateral circling;
grade 3: contralateral falling; grade 4: absence of spontaneous
movement or unconsciousness). The neuroscore was also used to
further confirm that successful thrombotic occlusion had been
achieved, since the existence of initial neurological deficit is a
reliable predictor for successful occlusion of the MCA [48,49];
only animals grade 2 or higher at 2 h were included in the study.
Exclusion of animals took place before assignment into the various
treatment groups.
Determination of infarct and edema volumes
At 24 h, the animals were euthanized; brains were removed,
cooled on ice, and then coronally cut into 2 mm-thick sections
using a tissue slicer, starting from 2 mm caudal to the frontal tip.
Sections were immediately stained with 2% 2,3,5-triphenyltetra-
zolium chloride (TTC, Sigma, St. Louis, MO) at 37uC for 10
minutes, then fixed in 4% phosphate-buffered formalin as
previously described [50]. Each slice was examined for subarach-
noid hemorrhage. Slices were scanned with a Coolpix camera
(Nikon, Sesto Fiorentino, Italy); infarct volume and brain edema
were measured using NIH ImageJ analysis software (available at
http://rsb.info.nih.gov/ij/). Ischemic volumes were calculated as
the sum of infarcted area (in mm
2) multiplied by slice thickness
(,2 mm). Edema volumes were calculated by subtracting the
contralateral hemisphere volume from the ischemic hemisphere
volume; for edema correction, the equation ischemic volume *
contralateral hemisphere/ipsilateral hemisphere volume was used,
as previously described [51]. Seven 2-mm thick slices were
measured for each brain.
ICH visual scoring
The severity of ICH was assessed as in Choudhri et al. with
some modifications [52]. Briefly, TTC-stained sections were
inspected by a blinded observer and the degree of ICH was given
a score based on maximal hemorrhage diameter measured on any
of the sections using NIH ImageJ software (ICH score 1: no
hemorrhage; score 2: ,1 mm; score 3: 1 to 2 mm; score 4: 2 to
3 mm; score 5: .3 mm).
Benefit index
The percentage of brain salvage (control ischemic volume - post
treatment ischemic volume/control ischemic volume) and the ICH
score were used to calculate a Benefit Index, as an overall measure
of treatment success. Similarly, a ‘‘Clinical Utility Index’’ has been
advocated as useful for drug development decisions [43].
Statistical analysis
Data are presented as mean6standard error of the mean
(SEM); all statistical analysis was conducted using SPSS package
(version 18, SPSS Inc., Chicago, IL, USA); differences were
considered statistically significant when p,0.05. The Shapiro-
Wilk and the Levene median tests were initially used to describe
the data distribution and to determine the equality of the
variances, respectively. In Part I, mortality rates in the groups
were compared using the Fisher’s exact probability test (two-
tailed). Non parametric approach was adopted to compare
differences in bleeding (Kruskal Wallis and Mann Whitney
statistics, when appropriate). In part II, the one-way ANOVA
was applied to determine for overall significant differences in
ischemic and edema volumes among groups, and to compare
Benefit Indices. Post-hoc analysis were conducted when p,0.05
by Fisher’s protected least significant difference (PLSD) test. Non-
parametric paired t-test (Wilcoxon signed rank test) was adopted to
evaluate differences in motor behavior in each group between 2 h
and 24 h.
Supporting Information
Figure S1 LDF variations after M5 15 mg/kg infusion.
A. Following clot injection, MCA occlusion is confirmed by
,75% drop of LDF signal. Compared to vehicle group, M5
15 mg/kg infusion adequately re-establish blood flow in MCA, as
confirmed by progressive rise of LDF over the next 60 minutes.
Recanalization was effective starting 30 to 40 minutes after MCA
occlusion was achieved (*p,0.05, **p,0.01). B: hemorrhagic
brains from group 3 (M5 alone), part I. Intense bleeding in this
group reflected aspecific activation of M5 inabsence ofC1-inhibitor
and caused 75% mortality due to massive hemorrhage, starting 30
minutes to 4 hours after treatment.
(TIF)
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